NRC AN 019

Drug Profile

NRC AN 019

Alternative Names: AN-019; NRC-AN-019; NRC/AN/019

Latest Information Update: 12 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Natco Pharma
  • Class Antineoplastics; Pyrimidines
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic myeloid leukaemia; Solid tumours

Most Recent Events

  • 11 Feb 2016 No development reported - Phase-II for Chronic myeloid leukaemia (Second-line therapy or greater) in India (PO)
  • 11 Feb 2016 No development reported - Phase-II for Solid tumours (Second-line therapy or greater) in India (PO)
  • 04 Jun 2013 Final efficacy, adverse events and pharmacokinetics data from a phase I trial in Chronic myeloid leukaemia presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top